Apollo Cytokine Research develops.

Apollo acquisition boosts NZ biotech Symansis New Zealand biotech Symansis has purchased Australian company Apollo Cytokine Study for A$500,000 to build on its unique cell signaling science and fast monitor expansion into new worldwide markets. Apollo Cytokine Research develops, manufactures and offers the world’s largest industrial range of individual cell-expressed glycoproteins for use in drug research, while Symansis produces antibodies that focus on molecules in growth factor, tension and cytokine signaling pathways http://meldonium.org here . Symansis CEO Dr Peter Foster stated the acquisition was a strategic proceed to expand its product offerings and advance both the company’s research program and business programs for growth.


To learn more about our pioneering science and our vital medications, visit.. Appeals Courtroom Affirms Patent Infringement Rulings Against Roche’s peg-EPO Product Amgen has announced that the Court of Appeals for the Federal Circuit affirmed the Massachusetts District Court’s decision that Roche’s peg-EPO item, Mircera, infringes four Amgen patents associated with recombinant erythropoietin and processes for making it. Regarding a 5th patent , the Federal government Circuit reversed the keeping of non-infringement by the District Courtroom and remanded that issue for a new trial allowing Amgen showing that Roche’s product infringes that patent aswell. The Government Circuit also affirmed the validity of Amgen’s patents except for a single issue of obviousness-type double patenting which only impacts Amgen’s later expiring patents .

Other entries from category "prosthetics":

Random entries